Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin in Subclinical Coronary Artery Disease (ASCAD-P)
NCT07524335Phase 3Recruiting
- Sponsor
- Montréal Heart Institute
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Montréal Heart Institute. Primary endpoint: Monthly Recruitment Rate at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
aspirin
03
Conditions
coronary artery disease (CAD)atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07524335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524335.